CryoLife Inc. (
Q3 2010 Earnings Call
November 04, 2010 10:00 am ET
Steve Anderson - President and CEO
Ashley Lee - EVP, COO & CFO
Joe Munda - Sidoti
Tim Lee - Piper Jaffray
Matt Palmer - Roth Capital Partners
Raymond Myers - The Benchmark Company
Greetings, and welcome to the CryoLife’s third quarter 2010 financial conference call. Now at this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instruction). As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host Steve Anderson, President and CEO for CryoLife. Thank you. You may begin.
Good morning everyone. This is Steve Anderson, CryoLife’s President and CEO, and I would like to welcome you to CryoLife’s third quarter 2010 conference call. With me today is Ashley Lee, Executive Vice President, COO and CFO.
The agenda for today’s call is as follows. Actually we will review today’s press release and we’ll comment on the company’s revenues by product line. We will also bring you up to date on the litigation and dispute with Medafor. I will discuss the recent Starch Medical transaction, the rollout of BioFoam in Europe, the status of the BioFoam clinical trials of the US and the recent approval of BioGlue in Japan.
After my comments, Ashley will return with financial guidance for the rest of 2010 and our initial forecast for 2011. After Ashley’s forecast comments are completed we will open the call for questions. At this time Ashley will discuss this morning’s press release and the company’s performance for Q3.